JUN 12, 2016 10:58 AM PDT

Parkinson's Disease: New Insights into α-Synuclein Toxicity

WRITTEN BY: Cassidy Reich
Parkinson’s disease is the second most common neurodegenerative disease, currently affecting ~ 1 million people in the United States. Just as with Alzheimer’s disease (the most common type of neurodegenerative disease), there are currently no treatments to slow Parkinson’s disease progression. Parkinson’s disease (PD) can be genetic, sporadic, or caused by exposure to certain pesticides. The disease pathology consists of degeneration of the dopamine-producing neurons in the substantia nigra, a region of the brain where voluntary movement is initiated. Exactly why these specific neurons are vulnerable is a big question in the PD research field.

          
Another major question in the field is how two of the main disease pathologies are connected. PD is characterized by Lewy bodies, which are aggregates of a protein called α-synuclein, and by mitochondrial dysfunction. A recent paper published in Science Translational Medicine has answered this question and characterized a mechanism that links α-synuclein and mitochondrial dysfunction.  
Mitochondria are double membrane-bound organelles that produce the energy that is used by the cell. As you’ve probably heard in high school biology, they are the “powerhouse” of the cell. They have their own DNA, but it only encodes 13 proteins, and up to 1,500 unique proteins are required for mitochondrial function. That means that efficient protein import is vital for mitochondrial function.

Researchers at the University of Pittsburgh School of Medicine have discovered that certain species of post-translationally modified α-synuclein bind to a mitochondrial import protein called TOM20 and that interaction leads to deficient respiration, increased production of reactive oxygen species (ROS), and a loss of mitochondrial membrane potential, all hallmarks of dysfunctional mitochondria.

            Schematic of mitochondria protein import.
When a protein is targeted to the mitochondria for import, it contains a mitochondria targeting signal (MTS) that is cleaved once inside the mitochondria to produce the mature, functional protein. The MTS motif has a very specific secondary structure in that it has a hydrophobic side and a hydrophilic side. The hydrophobic side interacts with TOM20 and then the hydrophilic side associates with a co-receptor, TOM22, before being translocated to TIM proteins on the inner membrane. The TIM proteins then translocate the MTS-tagged protein into the mitochondrial matrix. Certain post-translationally modified α-synuclein peptides adopt a conformation similar to known MTS motifs, bind to TOM20, prevent its interaction with TOM22, and impair mitochondrial protein import.  

This research is very exciting because it provides a link between α-synuclein and mitochondrial dysfunction and opens the door for new therapeutic strategies. It also helps to answer the question of why the dopaminergic neurons in the substantia nigra are so vulnerable. These neurons have been shown to express more α-synuclein than neurons in the surrounding midbrain and also have a higher state of oxidation to begin with. There is probably a destructive feed-forward cycle of excess post-translationally modified α-synuclein impairing mitochondrial protein import and causing more ROS to be produced which in turn causes cell-wide dysfunction. For therapeutics, the researchers overexpressed a naked MTS and saw that not only did it prevent α-synuclein binding to TOM20, but was also able to reverse the loss of the TOM20-TOM22 interaction caused by α-synuclein. The MTS is a small peptide and could potentially be developed as a disease-modifying PD therapeutic.

Sources: EurekAlert, Science Translation Medicine, Vereen (image 1 source), and ResearchGate (image 2 source)
About the Author
  • Cassidy is a curious person, and her curiosity has led her to pursue a PhD in Pharmacology at the New York University Sackler Institute of Biomedical Sciences. She likes to talk about science way too much, so now she's going to try writing about it.
You May Also Like
SEP 20, 2019
Genetics & Genomics
SEP 20, 2019
Do We Really Need Exercise?
We’ve all heard it; regular exercise is necessary for a healthy lifestyle. After all, physical fitness is typically related to better physical and me...
SEP 20, 2019
Drug Discovery & Development
SEP 20, 2019
The Composition of Cerebrospinal Fluid in MS patients Could Be The Key To Treatments That Halt Progression
The range of disability for individuals living with multiple sclerosis (MS) varies significantly depending on the relapsing/remitting form of the disease....
SEP 20, 2019
Drug Discovery & Development
SEP 20, 2019
Can LSD Treat Addiction?
Modern medicine commonly refers to addiction as a brain disease caused by drugs and other negative stimuli. However, evidence is surmounting that addiction...
SEP 20, 2019
Drug Discovery & Development
SEP 20, 2019
Why Drugs that Work on Mice Don't Work on Humans
Mice are used as the frontline for drug testing for brain disorders. Why? Their brains are supposed to have much of the same functioning as ours. Moreover,...
SEP 20, 2019
Genetics & Genomics
SEP 20, 2019
The Genetic Reasons Why Some People Need Less Sleep
Typically, people need between seven and eight hours of sleep per night to function properly. In  fact, reducing sleep by just one or two hours for a ...
SEP 20, 2019
Neuroscience
SEP 20, 2019
The brain of a psychopath: how people with psychopathic traits control their 'dark urges'
Psychopaths are usually portrayed negatively: they display antisocial behavior, such as shallow emotions, callousness, impulsivity, and lack of empathy. Ps...
Loading Comments...